Healthcare ❯ Pharmaceuticals

Vaccines

COVID-19 Vaccines COVID-19 Vaccine RSV Vaccine HPV Vaccine mRNA Technology Covid-19 HPV Vaccines Covid-19 Vaccine COVID-19 CSL's Seqirus Immunization Products Safety Data Covid Vaccine Combination Vaccines Regulatory Affairs Production Meningitis B Vaccine Specific Vaccines Vaccine Development Adult Immunizations COVID-19 Treatments Covid-19 Vaccines Injectable Treatments Mpox Vaccine Respiratory Diseases Influenza Vaccine Manufacturing Gardasil Sales Decline Flu Vaccination Public Health Vaccine Efficacy AstraZeneca Covid Vaccine Safety

Pfizer Posts Higher Q1 Sales but Lower Profit, Raising Fresh Questions About Its Dividend

Income investors face a tough tradeoff over thin coverage of the payout.

Moderna Reaches Up to $2.25 Billion LNP Patent Settlement, Pays $950 Million Upfront

Eli Lilly Tightens GLP-1 Grip, Guides Up to $83 Billion for 2026

Pfizer Sets 2026 Targets Below Wall Street as COVID Sales Fade, Patent Pressure Builds

Pfizer Lifts 2025 EPS Outlook, Targets $7.7 Billion in Savings as Dividend Draws Interest

Pfizer’s Updated COVID-19 Vaccine Shows Strong Phase 3 Immune Response for 2025–2026 Formula

Merck Launches $3 Billion Cost-Optimization Program Following Q2 Revenue Miss

House Judiciary Committee Subpoenas Pfizer Scientist Over 2020 Vaccine Timing Allegations